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Dermatopharmacokinetic Prediction of Topical Drug
Bioavailability In Vivo
Christophe Herkenne1,2, Aarti Naik1,2, Yogeshvar N. Kalia1,2, Jonathan Hadgraft3 and Richard H. Guy1,4
The overall goal of this study was to explore the potential of using stratum corneum (SC) tape-stripping, post-
application of a topical drug formulation, to derive dermatopharmacokinetic parameters describing the rate and
extent of delivery into the skin. Ibuprofen was administered in 75:25 v/v propylene glycol–water to the ventral
forearms of human volunteers for periods ranging between 15 and 180 minutes. Subsequently, SC was tape-
stripped, quantified gravimetrically, and extracted for drug analysis. Together with concomitant transepidermal
water loss measurements, SC concentration–depth profiles of the drug were reproducibly determined and
fitted mathematically. The SC-vehicle partition coefficient (K) and a first-order rate constant related to ibuprofen
diffusivity in the membrane (D/L2, where L¼ SC thickness) were derived from data-fitting and characterized the
extent and rate of drug absorption across the skin. Integration of the concentration profiles yielded the total
drug amount in the SC at the end of the application period. Using K and D/L2 obtained from the 30-minute
exposure, it was possible to predict ibuprofen uptake as a function of time into the SC. Prediction and
experiment agreed satisfactorily suggesting that objective and quantitative information, with which to
characterize topical drug bioavailability, can be obtained from this approach.
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INTRODUCTION
Bioavailability is defined as the rate and extent at which a
drug reaches the general circulation from an administered
dosage form. While this definition is adequate for systemi-
cally acting drugs given by, for example, the oral or
transdermal routes, its relevance to dermatological actives
applied and targeted to local skin sites is less clear. In
particular, the correlation between the availability of a
topically applied drug in the skin (and its therapeutic activity
at the site of action) with the resulting blood levels, has not
been established, primarily owing to analytical problems. It
follows that, until the relevance of systemic concentrations to
those of the drug within, for example, the viable epidermis,
can be shown, the evaluation of topical bioavailability must
involve quantification of the target tissue itself; that is, one or
more components of the skin adjacent to the application site.
Although skin biopsy is a logical solution to this challenge
(Schaefer et al., 1987; Parry et al., 1992; Marks and Dykes,
1994; Schrolnberger et al., 2001), the approach is invasive
and unacceptable for routine use, such as the need to perform
repeated biopsies to characterize a dermatopharmacokinetic
(DPK) drug concentration versus time profile. Alternative
strategies are limited. For instance, the use of a drug’s
pharmacodynamic response (e.g., the vasoconstriction in-
duced by corticosteroids) is a legitimate strategy unfortu-
nately constrained to only a very limited number of drug
classes (Haigh and Kanfer, 1984; Chan and Li Wan Po, 1992;
Pershing et al., 1992a, b; Shah, 1998). Microdialysis is
another technique, attracting significant interest at this time,
and can be used in vivo in humans (Anderson et al., 1991,
1994; Ault et al., 1994; Benfeldt et al., 1999); however, the
method is technically demanding and again results in
significant analytical chemistry challenges when the drug’s
lipophilicity is high, and its skin permeation slow (a not
unusual combination, as it turns out).
However, in 1998, the Food and Drug Administration
(FDA) released a draft guidance proposing a DPK method for
evaluating bioavailability and/or bioequivalence of topical
dermatological drug products (Shah, 1998). As specified in
this document, the method measures topically applied drug
levels in the outermost layer of the skin, the stratum corneum
(SC), in vivo as a function of time post-application and post-
removal of the formulation, so as to generate an SC
concentration versus time profile from which the maximum
amount in the SC (Cmax), the time at which Cmax is observed
(i.e., Tmax) and the area under the curve (AUC) can be
obtained. The SC is collected by successive application and
removal of adhesive tape providing a minimally invasive
technique by which the drug’s concentration in the skin can
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be determined. The DPK method assumes that: (a) in normal
circumstances, the SC is the rate-determining barrier to
percutaneous absorption, (b) the SC concentration of drug is
directly related to that which diffuses into the underlying
viable epidermis, and (c) SC drug levels are more useful and
relevant for assessing local, dermatological efficacy than
plasma concentrations.
The objectives of the research described here were to
examine the value of the information provided by a DPK
experiment, and to investigate whether a more profound
analysis of the data might allow increased insight and
enhancement of the efficiency of the approach, specifically
by showing that shorter-duration studies may be predictive
of the behavior seen with longer application times. The
results were used to determine key diffusional and parti-
tioning parameters for the drug, together with an idea of
the error involved in their assessment; in turn, this has
permitted the limitations of the DPK approach to be
evaluated, for example, with respect to its ability to
distinguish between the performance of two bioequivalent
(or inequivalent) formulations.
RESULTS AND DISCUSSION
Deduced partitioning (K) and diffusion parameters (D/L2)
The SC concentration–depth profiles for seven subjects
following a 30-minute application of ibuprofen in 75:25 v/v
propylene glycol (PG)–water are shown in Figure 1a. The best
fits of equation (5) to the results are drawn through the
individual data points and the deduced values of K and D/L2
are in Table 1. It is fair to say that the reproducibility of these
in vivo measurements was quite reasonable, suggesting that
the tape-stripping procedure was consistently performed.
Inter-subject variability corresponded, at most, to a coeffi-
cient of variation of 30%; typically, it fell in the range of
15–20%. When repeat measurements have been made using
the same volunteer, the intra-subject coefficient of variation is
5–10%. The mean value of the SC/vehicle partition coeffi-
cient was 2.8 (70.3), indicating a slight preference of the
drug for the SC over the formulation; this finding reflects the
similarity between the solubility parameters of ibuprofen and
skin (9.65 (cal cm3)1/2 (Bustamante et al., 2000) and about
10 (cal cm3)1/2 (Liron and Cohen, 1984), respectively) and
the difference between these values and that of 75:25 v/v PG/
water (B17 (cal cm3)1/2). The average D/L2 obtained was
0.12 (70.05) hour1; this diffusion parameter is effectively a
first-order rate constant describing drug absorption across the
skin. This kinetic constant is related to the classic diffusional
lag-time (Tlag¼ L2/6D) (Roberts et al., 1999), and implies a
value of B1.4 hours. In turn, this means that ibuprofen
requires between 3.5 and 4 hours (i.e., about 2.7 Tlag (Roberts
et al., 1999)) to achieve steady-state diffusion across the skin.
The latter conclusion is confirmed in Figure 1b, which shows
the average SC concentration–depth profiles of ibuprofen as a
function of the time of application between 15 and
180 minutes. The mean values were obtained by substituting
the average values of K and D/L2 (derived from fitting the
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Figure 1. Ibuprofen concentration profiles across the SC. (a) Individual SC concentration–depth profiles for seven subjects following a 30-minute application of
ibuprofen in 75:25 v/v PG–water. (b) Average SC concentration–depth profiles (n¼ 4–7). The ibuprofen formulation was applied for periods ranging from
15 minutes to 3 hours.
Table 1. Partitioning (K) and diffusion (D/L2)
parameters1
Subject K D/L2 (hour1)
1 2.75 0.136
2 3.02 0.100
3 3.17 0.086
4 3.14 0.049
5 2.57 0.162
6 2.25 0.188
7 2.84 0.125
1Values were obtained by fitting equation (5) to SC concentration–depth
profiles of ibuprofen after application of a saturated solution in 75:25 v/v
PG–water for 30 minutes. The results from seven subjects are presented.
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individual subjects’ concentration profiles, and presented in
Table 2) together with the appropriate values of time into
equation (5). This process generates a smooth profile of Cx as
a function of x/L. The profile observed at 3 hours is nearly
linear.
An idea of the scatter around the mean profiles can be
appreciated from Figure 1a and the fitted parameters in
Table 2. Analysis of variance indicates that the partitioning
and diffusion parameters did not change significantly with the
application time of the formulation. This means that the drug
rapidly equilibrated between the vehicle and the SC at the
skin surface and that the formulation itself had no clear
penetration-enhancing effect.
Prediction of AUC as a function of time
In light of the observations reported above, the potential
to predict the preferred DPK parameter (i.e., the AUC,
equation (6)) is clear. Using the K and D/L2 values deduced at
30 minutes, together with their associated variabilities, it
was possible to predict the theoretical evolution of the AUC
as a function of time, together with the ‘‘tolerance’’ of the
model.
Figure 2a shows six calculated evolutions of the AUC over
time. The two solid lines are the predictions using the mean
value of K from the 30-minute data (2.8) and either the mean
value of D/L2 plus its associated standard deviation (SD) or
the mean D/L2 minus its SD (see Table 1); the gray lines were
determined using the average D/L2 at 30 minutes
(0.12 hour1) and either the mean value of K plus its
associated SD or the mean K minus its SD. Finally, the
dashed curves represent the entire ‘‘tolerance’’ of the model
with the upper curve using the mean values of K and D/L2
plus their associated SDs, and the lower curve being
calculated with the average partitioning and diffusion
parameters minus their SDs. The extent to which the
experimentally determined AUCs are predicted by the model
is illustrated in Figure 2b and Table 2; all the mean values of
AUC fall within the limits of the model, with only a few
individual values just outside. Figure 2a also demonstrates
that, whereas the kinetic parameter influences the rate at
which the limiting value of AUC (¼KCv/2) is attained, it is K
which defines the value of this plateau. It follows that the
importance of the variability in D/L2 is felt more keenly at
shorter times, but then becomes progressively less and less
significant. Indeed, as noted in Table 2, it is not possible to
determine D/L2 from the fit to the SC concentration–depth
profile at 180 minutes; by this time, the exponential function
in equation (5) is negligible and the concentration profile
close to linear (Figure 1b). The data contain essentially no
Table 2. Derived partitioning (K) and diffusion (D/L2)
parameters (mean7SD; n=4–7) as a function of skin
exposure duration1
Application
time (min) K D/L2 (hour1) AUC (M)
Predicted
AUC (M)
15 2.870.5 0.1570.09 0.1070.03 0.10
30 2.870.3 0.1270.05 0.1370.02 —
45 3.170.4 0.1170.05 0.1870.03 0.16
60 3.070.4 0.1370.05 0.2070.02 0.18
75 3.270.6 0.0870.02 0.1970.02 0.20
90 3.470.4 0.0770.03 0.1970.02 0.21
180 3.070.3 — 0.2570.04 0.24
1Results obtained by fitting equation (5) to SC concentration–depth
profiles of ibuprofen after application periods ranging from 15 to
180 minutes. The experimentally measured, integrated concentrations of
drug in the SC (AUC) as a function of time are also shown and are
compared to predicted values obtained using equation (6) with the values
of K and D/L2 determined from the 30-minute data.
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Figure 2. Evolution of AUC as a function of time. (a) The curves were determined from the K and D/L2 values, and their respective variances, deduced from the
SC concentration–depth profiles obtained after 30 minutes (Figure 1a). The solid lines are the predictions using the mean K and the extreme values of D/L2
(meanþ SD, meanSD); the gray lines use the mean D/L2 and the extremes of K; the dashed lines are the results when the extremes of both K and D/L2 are used.
(b) Comparison of experimental and predicted AUC values. The individual (n¼4–7) experimentally determined AUCs as a function of time are plotted together
with the mean prediction (central curve), and the limits, of the predictions based on the 30-minute K and D/L2 values.
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‘‘information’’ about D/L2 as a result and the drug distribution
profile across the SC is approximated by:
Cx ¼ KCvð1  x=LÞ ð1Þ
which is an equation of a straight line, the value of Cx
decreasing from KCv at the skin surface (x/L¼0) to zero at
x¼ L (x/L¼1). Exactly this behavior has been observed in
recently reported experiments both in vivo in human
volunteers, and ex vivo in pig skin (Herkenne et al., 2006a).
The impact of the variability in K on the predicted
evolution of the AUC increases with increasing time up to a
limiting value, which coincides effectively with the
point at which the effect of D/L2 on the concentration
profile becomes insignificant. Propagation of errors in D/L2
and K, therefore, means that the overall tolerance
of the predictive model increases quite rapidly with time at
first, before passing through a maximum value and eventually
settling at a fixed level. This behavior is illustrated graphically
in Figure 3, and is favorably compared to the measured
experimental errors observed in this work at different
application times.
Clearly, however, the predictive power of the approach
must depend sensitively on the quality of the data chosen to
provide the K and D/L2 values (and their respective
variabilities). If K and D/L2 at 30 minutes, for example, are
associated with very large error, then the certainty with which
predictions of AUC may be made at other times will be
reduced. The decision to choose a 30-minute exposure as the
defining period in this study was somewhat arbitrary, being a
balance between the desire to choose a period short enough
that predictions over a reasonable period before steady-state
is reached could be made, and long enough to allow the SC
concentration–depth profile to be easily quantifiable from an
analytical point of view. As stated above, when the
concentration–depth profiles obtained at different times were
individually fitted, there were no statistically significant
differences (P40.05) between the values of either K or D/L2
determined at 15, 30, 45, and 60 minutes (i.e., periods that
may be considered to be ‘‘short’’ contact times). It follows
that using the partitioning and diffusion parameters at any of
these times to predict the evolution of the AUC from 0 to
180 minutes would generate results not dissimilar to those in
Figure 2b. Effectively, only the limits on the prediction would
be noticeably different, owing to differences in the variances
of the specific K and D/L2 values deduced at the different
times. Figure 4 illustrates this discussion: the mean values of
predicted AUC do not deviate appreciably from one another
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Figure 3. Impact of variability in K and D/L2. The propagation of errors in
both parameters, as a function of time, is illustrated. The effect of the diffusion
parameter is felt most keenly at earlier times, and then diminishes to an
insignificant amount. The impact of K increases steadily up to a plateau and
eventually dominates. The mean experimentally determined errors are shown
for comparison.
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Figure 4. Predicted evolution of AUC as a function of time. (a) Predictions based upon the average values of K and D/L2 (see Table 2) determined from fitting
the SC concentration–depth profiles obtained after application times of 15, 30, 45, and 60 minutes. (b) Limits of the predicted evolution of AUC with time.
Predictions based upon the variances in the values of K and D/L2 (see Table 2) determined from fitting the SC concentration–depth profiles after short-term
applications of the ibuprofen formulation.
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(Figure 4a), whereas the tolerance of the model shows more
significant variation (Figure 4b).
Practical significance of the results
From a pragmatic standpoint, the results presented here have
utility with respect to the potential application of a DPK
approach to the assessment of topical bioavailability and
bioequivalence. First of all, the fact that the evolution of the
AUC profile may be predicted up to the attainment of steady-
state, using the parameters K and D/L2 obtained from a
relatively short-contact experiment, would greatly simplify
the originally envisaged procedure described in the guidance
document (Shah, 1998). In other words, it should be possible
to characterize the ‘‘absorption phase’’ of a drug following its
administration to the skin by the measurement and analysis of
the resulting SC concentration–depth profile at a judiciously
selected time.
Second, it is clear that the methodology adopted, whereby
all the information obtained in a tape-stripping experiment is
used constructively (i.e., the profile of the drug as a function
of position in the SC is analyzed and interpreted rather than
simply determining the integrated amount in the entire
barrier) can allow for more sophisticated data treatment and
the extraction of diffusion and partition parameters, which
report directly on the rate and extent of drug delivery into the
skin. As reported previously (Alberti et al., 2001b), the
manner in which K and D/L2 may be altered by the vehicle, in
which a particular drug is applied, can also reveal mechanis-
tic information about the interaction of the formulation
excipients with the SC. Objective evaluation and criteria for
bioequivalence between different products should therefore
be possible. The latter potential has been demonstrated
recently using four commercially available, topical ibuprofen
products (Herkenne et al., 2006b).
Third, the approach should permit the better design of
experiments and the more realistic interpretation of the data
obtained. With respect to the former issue, the results
presented illustrate the importance of judiciously choosing
the appropriate time(s) at which to make DPK measurements.
The SC concentration–depth profiles are valuable tools with
which to estimate both thermodynamic and kinetic para-
meters, but the optimal time to tape-strip is a balance
between analytical chemistry demands and the closeness of
the approach to steady-state. It should also be remembered
that the tape-stripping procedure requires a finite amount of
time to perform; that is, the application time of the
formulation should not be so short that the subsequent
removal of the SC requires a significant fraction of that
period. Otherwise, it is possible that the concentration–depth
profile will alter significantly while tape-stripping is being
performed (Reddy et al., 2002). There is a ‘‘window of
opportunity’’, therefore, in which to perform the most
informative experiments. It is important to note that although
this optimum for ibuprofen can be set at about 30 minutes,
this will not be the case for all drugs.
The latter point can be illustrated by reference to
equation (6), which can be expressed in the simplified form
below:
AUC ¼ KCv½12  fðtÞ ð2Þ
where
f ðtÞ ﬃ 4
p2
exp  D
L2
p2t
 
þ 1
9
exp 9 D
L2
p2t
  
ð3Þ
With increasing time, f(t) decreases toward zero, and AUC
reaches its limiting value of KCv/2. The contribution of f(t) (as
a percentage, %f(t)) to the absolute value of the AUC is
therefore given by:
%f ðtÞ ¼ 100 f½KCv=2  ½KCvð
1
2  f ðtÞÞg
KCv=2
¼ 100 f ðtÞ
1
2
ð4Þ
Graphically, this contribution can be visualized in the
theoretical concentration–depth profiles shown in Figure 5a.
15 minutes
30 minutes
45 minutes
60 minutes
75 minutes
90 minutes
180 minutes
Theoritical SC profiles
0.6 100
80
60
40
20
0 20 40 60 80 100 120 140 160 120
0.5
0.4
0.3
0.2
0.1
0.0 0.2 0.4 0.6 0.8 1.0
Ib
u
pr
of
e
n
 c
o
n
ce
n
tra
tio
n 
in
 S
C 
(M)
x/l Time (minutes)
D/L2=0.06 h–1
D/L2=0.12 h–1
D/L2=0.24 h–1
R
el
at
ive
 c
o
n
tri
bu
tio
n 
of
 D
/L
2  
fu
nc
tio
n
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
to
 th
e 
to
ta
l A
UC
a b
Figure 5. Theoretical SC concentration–depth profiles for ibuprofen. The calculations are based on drug delivery from a saturated solution in 75:25 v/v
PG–water (K¼ 2.8, D/L2¼0.12 hour1). (a) The function f(t) is the difference between the area under the linear, steady-state profile and that under the curvilinear
profiles at shorter times. (b) Contribution of f(t) to the total AUC as a function of time. Calculations are shown for three values of D/L2: (i) that obtained for
ibuprofen from the 30-minute exposure experiments reported here (0.12 hour1), (ii) 0.24 hour1, and (iii) 0.06 hour1. The times at which %f(t)¼50% are
shown.
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The function f(t) corresponds to the difference between the
area under the limiting, linear profile observed at steady-state
(which is attained at tB2.7  (L2/6D)) and that under the
curvilinear profiles attained at shorter times in the gradual
approach to steady-state. The manner, in which %f(t)
depends upon the value of the diffusion parameter, is
demonstrated in Figure 5b for three different values of D/L2:
(i) that obtained for ibuprofen from the 30-minute exposure
experiments reported here (0.12 hour1), (ii) 0.24 hour1, and
(iii) 0.06 hour1. It can be seen that even a simple factor of
two difference in this parameter shifts significantly the
relative contribution of f(t) as a function of time. At
25 minutes, with D/L2¼0.12 hour1, %f(t) is B50%; if D/L2
is twice this value, then %f(t) decreases more rapidly, passing
the 50% level at only 12.5 minutes. In contrast, for a diffusion
parameter that is one-half of that observed for ibuprofen, the
decay of the %f(t) function is slower and the 50% mark is
reached only after 50 minutes; it follows, in this case, that it
may be appropriated to perform the pivotal DPK measure-
ment at this longer time.
CONCLUSION
The research presented demonstrates that the tape-stripping
approach can be used to derive useful DPK parameters,
specifically the SC-vehicle partition coefficient (K) of the
drug, and its ‘‘diffusion kinetic’’ (D/L2). Expressing the
permeant’s concentration as a function of normalized
distance into the SC results in reproducible data and
reasonable inter-subject variability, demonstrating that quan-
tification of the SC removed in the tape-stripping procedure is
very important. The stability of K and D/L2 values as a
function of time indicates, respectively, whether the drug
distributes rapidly from the formulation into the SC at the skin
surface, and whether there are interactions between the
vehicle constituents and the skin that may alter the
permeability of the membrane. As a result, these key
thermodynamic and kinetic parameters should be suitable
criteria with which to assess bioequivalence (or not) between
different formulations of the same drug.
It has been further demonstrated here that the values of K
and D/L2, determined from a specific (and relatively short)
application time, can be used to predict the entire absorption
profile of the drug up to steady-state. The potential to
dramatically simplify the DPK methodology is apparent,
therefore, and worthy of considerable further study. It is also
clear that the DPK parameters derived have considerable
value in terms of experimental design and the timing of the
most informative tape-stripping measurements. Further vali-
dation work, of course, remains to be performed. The
approach must be extended to other drugs, of different
physicochemical properties, and to more ‘‘real-life’’ formula-
tions, including the use of finite, rather than the infinite, doses
used in this work; it is important too to examine whether the
homogeneity of the SC assumed here is a reasonable model
for drugs other than ibuprofen. Nevertheless, it would appear
that the DPK technique has considerable potential to provide
a facile and objective approach to the determination of
topical drug availability, to the optimization of topical
formulations, and to the evaluation of bioequivalence of
topical drug products.
MATERIALS AND METHODS
Chemicals
S-(þ )-Ibuprofen was from Fluka (Buchs, Switzerland), PG from
Sigma-Aldrich (Steinheim, Germany). Extraction of ibuprofen from
the adhesive tape strips and liquid chromatographic analysis were
performed with HPLC grade milli-Q water and acetonitrile (Sigma-
Aldrich). The buffer used was prepared with citric acid monohydrate,
sodium hydroxide (Sigma-Aldrich), and hydrochloric acid (Fluka).
A saturated solution of ibuprofen was prepared by stirring an
excess of drug in 75:25 v/v PG–water in a thermostatted oven (Forma
Scientific, Marietta, OH) at 20 (71)1C for 4 days. After centrifugation
(15 minutes at 3,000 r.p.m.), the supernatant was passed through a
0.45mm nylon Acrodisc filter (Pall, Basel, Switzerland). The
saturation solubility of ibuprofen was measured by HPLC at
227 nm (maximum wavelength) after adequate dilution. Ibuprofen
concentrations at saturation were determined by measuring the
absorbance of saturated solutions and back calculation. Three
replicate measurements were performed; the saturation solubility
of the drug was 35.7 mg/ml in 75:25 PG–water.
Experimental procedures
Ten volunteers (seven female, three male, 24–46 years) with no
history of dermatological disease gave written, informed consent and
participated in the study, which was approved by the ethical
committee of the Hoˆpitaux universitaires de Gene`ve and was
conducted according to the Declaration of Helsinki Principles. The
skin sites used were non-hairy regions (4 5 cm) of the ventral
forearm. Treatment involved application of 1.9 ml of ibuprofen
solution, via a cellulose gauze (Tela, Basel, Switzerland), which was
subsequently covered by an occlusive polyester film (Scotchpak,
3M, St Paul, MN) and affixed to the skin with adhesive polyurethane
(Opsite, Smith & Nephew, Hull, UK). After the chosen contact time,
the patch was removed and excess formulation gently removed using
three dry cellulose swabs.
SC sampling protocol
To deduce the concentration profile of ibuprofen across the SC
following drug application, the barrier was progressively removed
with adhesive tape-stripping (Scotch Book Tape, 3M, St Paul, MN).
The SC sampling site was delimited by a template to leave
an exposed skin area which was less than that treated with
the formulation. The template, consisting of tape from which a
hole had been cut in the middle, was centered over the
drug application site immediately before tape-stripping began. The
size of the opening in the template (2 2.5 cm2) was smaller
than that of the tape-strips. The amount of SC removed on each tape-
strip was measured by the difference between the pre- and
post-stripping weight of the tape (Mettler AT 261 balance,
Greifensee, Switzerland). From this mass, and the area of the tape
and, given that the density of SC is B1 g cm3 (Anderson and
Cassidy, 1973), it was possible to calculate the SC thickness
removed on each strip, and hence the corresponding position (or
depth, x) within the barrier.
The apparent SC thickness (L) was determined from measure-
ments of transepidermal water loss (TEWL) (Servomed Evaporimeter
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EP2, Varberg, Sweden) during the stripping of the SC (Kalia
et al., 1996, 2000). This meant that ibuprofen concentration profiles
across the barrier could be presented as a function of relative depth
into the SC (varying from x/L¼ 0 at the skin surface to x/L¼ 1
at the SC–stratum granulosum interface), allowing thereby normal-
ization of the results from different volunteers. The TEWL measure-
ments were made at sites adjacent to the treated areas for two
reasons: (i) both water and PG are somewhat volatile and
their evaporation from the SC during tape-stripping from the
formulation-treated skin resulted in artifactual TEWL values; (ii) to
allow time for the TEWL values to stabilize, a period of about
2 minutes is required between each tape-strip – for the shorter
application times considered, therefore, the time needed to strip
the SC became long compared to the period for which the
formulation was in contact with the skin, a clearly unacceptable
situation. The number of tape-strips removed from each volunteer
ranged from 10 to 30, and was typically around 15, and
was a function of SC thickness; however, it was unnecessary to
completely remove the SC – the data analyses employed, both for
the determination of SC thickness, and for the interpretation of
concentration–depth profiles, do not require complete ablation of the
barrier to yield valuable information. Tape-stripping was stopped
either when the volunteer expressed discomfort (and, clearly,
there is variability in this threshold), or when the value of
TEWL exceeded six times the baseline, pre-stripping level (by which
time at least 75–80% of the SC had been removed (Kalia
et al., 2000)). Distinct from the FDA guidance, the amount of
ibuprofen on all tape-strips was determined and used in the
subsequent data analysis; no information was discarded; therefore,
and any drug not removed by the surface cleaning process at the end
of the treatment period was assumed to eventually become
bioavailable in the skin.
All experimental procedures (ibuprofen application and SC
sampling, as well as TEWL measurements) were performed
in a single, air-conditioned room in which the temperature was
23721C.
Extraction and analysis of ibuprofen in the tape strips
After reweighing, the tape-strips were rolled and inserted into 1.5 ml
HPLC vials. Ibuprofen was then quantitatively extracted from the SC
on the strips by submersion in a 90:10 v/v mixture of acetonitrile and
1 M hydrochloric acid for 12 hours. The extraction procedure was
validated by spiking tape-stripped samples of untreated SC with
known amounts of drug, chosen to represent the expected range of
concentrations encountered in the in vivo experiments. The
extracted solutions did not require filtration; they were optically
clear and contained a negligible amount of protein (Biorad protein
assay kit, Hercules, CA). The efficiency of the extraction procedure
was indistinguishable from 100%.
Extracted ibuprofen was analyzed by HPLC with UV detection at
227 nm (Machery Nagel (Hoerdt, France) CC125/4 Nucleosil 120-3
C18 column; Dionex (Sunnyvale, CA) AD 25 detector). The isocratic
mobile phase was a 55:45 (v/v) mixture of acetonitrile and 0.1 M
citrate buffer at pH 2.4. With a flow rate of 1.1 ml/minute, at room
temperature, the retention time of ibuprofen in a 50 ml sample was
about 4.5 minutes. Peak recording and data processing were
performed with the built-in system manager. Ibuprofen was
determined using the AUC method and calibration plots were
generated with the neat compound. The limit of quantification was
0.5 mg/ml.
Experimental strategy and data analysis
The SC concentration (Cx) versus normalized depth (x/L) profile of
ibuprofen was determined as a function of application time of the
formulation (15, 30, 45, 60, 75, 90, and 180 minutes). It was not
possible to use every subject at every time-point considered. Rather,
subjects were assigned randomly to the experiments conducted at
different times; the sites of application on the forearm used were also
varied randomly. The minimum and maximum numbers of subjects,
who took part in an experiment at a particular time, were four and
seven, respectively. The results were fitted to the appropriate
solution of Fick’s second law of diffusion (Alberti et al., 2001a) with
the following boundary conditions: (a) that the applied drug
concentration (Cv) remains constant throughout the application
period (t); (b) that the viable epidermis acts as a perfect sink for the
drug (i.e., Cx¼ 0 at x¼ L); (c) that the SC contains no drug at t¼ 0.
The model also assumes that the SC is a homogeneous membrane,
an approximation that is clearly a significant simplification of reality
(Anissimov and Roberts, 2004) (in that the stratum granulosum–SC
interface is quite different from the stratum disjunctum at the surface
and demonstrates the obvious heterogeneity of the barrier). Never-
theless, as is apparent from the results, which do fit this simplified
approach (both for ibuprofen, as reported here, and for other drugs as
well (Alberti et al., 2001a; Moser et al., 2001)), a model in which
both partitioning and diffusivity are treated as position-dependent
parameters is more sophisticated than can be justified by the quality
and inherent variability of in vivo measurements. As for the
interpretation of TEWL data as a function of the fraction of SC
removed (Kalia et al., 1996), the results are therefore analyzed with a
solution to Fick’s law of diffusion that considers the barrier to be
uniform. The resulting equation
Cx ¼ KCv 1  x
L
 
 2
p

X1
n¼1
1
n
sin
npx
L
 
exp
Dn2p2t
L2
 ( )
ð5Þ
allows determination of the drug’s SC/vehicle partition coefficient (K)
and a kinetic parameter (D/L2) which characterizes the
rate of diffusion of ibuprofen across the SC. Integration of
equation (5) across the SC thickness (i.e., from x¼ 0 to x¼ L) yields
the total concentration of drug in the SC (AUC) after an application
time t:
AUC ¼
Z1
0
Cx dðx=LÞ
¼ KCv 1
2
 4
p2
X1
n¼0
1
ð2n þ 1Þ2 exp 
ð2n þ 1Þ2p2Dt
L2
 !( ) ð6Þ
AUC represents, therefore, the uptake of ibuprofen into the skin and
is the proposed metric for evaluation in the proposed DPK method of
the FDA (Shah, 1998).
In the experiments performed in this study, the best-fit values of K
and D/L2 were derived from the SC concentration versus x/L profiles
measured at different times t and then substituted into equation (6) to
calculate the corresponding AUCs. These results were then
compared to the AUCs predicted by equation (6) using the K and
D/L2 parameters derived from the 30-minute experiment. The
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hypothesis tested here is that the thermodynamic and kinetic
parameters (K and D/L2, respectively) characterizing the extent and
rate of ibuprofen uptake into the SC are invariant over the range of
application times examined, and that a relatively short-contact
exposure can therefore be used to predict the complete absorption
profile of the drug. The degree of agreement between prediction and
experiment should reveal, for example, whether the drug quickly
attains equilibrium between the formulation and the SC at the skin
surface (as is typically assumed), or if there are excipients in the
vehicle which are released into the SC and alter its diffusional barrier
characteristics (Alberti et al., 2001c).
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